Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HPC+ in the medical field: Overview and current examples.
Koch M, Arlandini C, Antonopoulos G, Baretta A, Beaujean P, Bex GJ, Biancolini ME, Celi S, Costa E, Drescher L, Eleftheriadis V, Fadel NA, Fink A, Galbiati F, Hatzakis I, Hompis G, Lewandowski N, Memmolo A, Mensch C, Obrist D, Paneta V, Papadimitroulas P, Petropoulos K, Porziani S, Savvidis G, Sethia K, Strakos P, Svobodova P, Vignali E. Koch M, et al. Among authors: fink a. Technol Health Care. 2023;31(4):1509-1523. doi: 10.3233/THC-229015. Technol Health Care. 2023. PMID: 36641699 Free PMC article. Review.
Colonoscopy and Subsequent Risk of Parkinson's Disease.
Holtz AV, Fink A, Tamgüney G, Doblhammer G. Holtz AV, et al. Among authors: fink a. J Parkinsons Dis. 2024 Apr 24. doi: 10.3233/JPD-240017. Online ahead of print. J Parkinsons Dis. 2024. PMID: 38669559
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
Dannehl D, Jakob D, Mergel F, Estler A, Engler T, Volmer L, Frevert ML, Matovina S, Englisch A, Tegeler CM, Rohner A, Seller A, Hahn M, Pfister K, Fink A, Popp I, Lorenz S, Tabatabai G, Juhasz-Böss I, Janni W, Brucker S, Taran FA, Hartkopf A, Schäffler H. Dannehl D, et al. Among authors: fink a. ESMO Open. 2024 Apr 17;9(5):102995. doi: 10.1016/j.esmoop.2024.102995. Online ahead of print. ESMO Open. 2024. PMID: 38636292 Free PMC article.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter MA, Niemann CU, da Cunha-Bang C, Kater AP, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, Hallek MJ. Langerbeins P, et al. Among authors: fink am. Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564. Online ahead of print. Blood. 2024. PMID: 38620092
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, Schilhabel A, Brüggemann M, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. Fürstenau M, et al. Among authors: fink am. Blood. 2024 Apr 15:blood.2023022730. doi: 10.1182/blood.2023022730. Online ahead of print. Blood. 2024. PMID: 38620072
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, Langerbeins P, Fischer K, Kreuzer KA, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M. Cramer P, et al. Among authors: fink am. Am J Hematol. 2024 Apr 5. doi: 10.1002/ajh.27304. Online ahead of print. Am J Hematol. 2024. PMID: 38578022 No abstract available.
1,337 results